Description:
MK-2206 is a highly selective Akt inhibitor with IC50 of 8 nM, 12 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. It is undergoing a phase II clinical trial for the treatment of ovarian, fallopian tube, or primary peritoneal cancer where there are mutations in P13K or AKT or low levels of PTEN.
- Molecular Weight:480.4
- Purity:>98%
Molecular Formula:
C25H23Cl2N5O
Canonical SMILES:
C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl
InChI:
InChI=1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H
InChIKey:
HWUHTJIKQZZBRA-UHFFFAOYSA-N
Appearance:
White Solid
Synonyms:
MK-2206. MK 2206. MK2206. Weitere Informationen finden Sie
hier